Sugi Predict

Sugi Predict / Compounds / SCHEMBL10440862

SCHEMBL10440862

SCHEMBL10440862

CC(=O)OC1COCC1OC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 5/20 0.42
▸ CHRM1 P11229 3/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CHRM4 P08173 2/20 0.38
▸ CHRM3 P20309 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.35
▸ BCHE P06276 1/20 0.35
▸ POLB P06746 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10440860 0.89 CHRM2 (0.36) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL29189672 0.88 CHRM2 (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL20329541 0.88 POLB (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL6475002 0.88 POLB (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL24145355 0.88 POLB (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL24752585 0.88 CHRM2 (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL14627937 0.88 CHRM2 (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL220405 0.88 POLB (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL29189673 0.88 CHRM2 (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6
SCHEMBL17928956 0.88 POLB (0.38) CHRM2CHRM1KMT2AMEN1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3801538-B1 TLR7 AGONISTS PRIMMUNE THERAPEUTICS INC (US) 2024-10-02 — — EP claimed
EP-4512816-A2 TLR7 AGONISTS Primmune Therapeutics, Inc. (US) 2025-02-26 — — EP disclosed
US-12018043-B2 CD73 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
WO-2024120464-A1 NUCLEOTIDE ANALOG, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2024-06-13 — — WO disclosed
WO-2024076873-A1 HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE TEON THERAPEUTICS, INC. (US) 2024-04-11 — — WO disclosed
US-11858956-B2 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections SOUTHERN RESEARCH INSTITUTE (US) 2024-01-02 — — US disclosed
US-11807658-B2 CD73 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
WO-2023131254-A1 PSEUDOURIDINE MODIFIED AT N1 POSITION AND USE THEREOF IN MRNA SYNTHESIS 上海吉量医药工程有限公司 2023-07-13 — — WO disclosed
WO-2023106842-A1 BENZIMIDAZOLE DERIVATIVE COMPOUND AND USE THEREOF (주) 팜젠사이언스 2023-06-15 — — WO disclosed
US-11660311-B2 Cyclic dinucleotides as anticancer agents BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-30 — — US disclosed
EP-4107164-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 — — EP disclosed
WO-2022237747-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF 四川海思科制药有限公司 2022-11-17 — — WO disclosed
CN-115135383-A Antiviral compounds 吉利德科学公司 2022-09-30 — — CN disclosed
CN-115087659-A Antiviral compounds 吉利德科学公司 2022-09-20 — — CN disclosed
US-20220259253-A1 CD73 INHIBITORS ORIC PHARMACEUTICALS, INC. 2022-08-18 — — US disclosed
US-20220220147-A1 CD73 INHIBITORS ORIC PHARMACEUTICALS, INC. 2022-07-14 — — US disclosed
US-20220204545-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS OREGON HEALTH AND SCIENCE UNIVERSITY 2022-06-30 — — US disclosed
US-20220117995-A1 CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS BRISTOL MYERS SQUIBB CO (US) 2022-04-21 — — US disclosed
CN-109503587-A The antitumor action of double heterocycle ribavirin analogs and application 辽宁利锋科技开发有限公司 2019-03-22 — — CN disclosed
EP-0403938-A2 Diphenyl ether derivative, herbicidal composition containing the derivative as active ingredient, and process for producing the derivative MITSUBISHI KASEI CORPORATION (JP) 1990-12-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204545-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS MTAP, GALE, TPMT CHRM2 1101/4885CHRM1 697/4885KMT2A 536/4885
US-11807658-B2 CD73 inhibitors ENTPD5, NT5E, ENTPD1 CHRM2 1316/4885CHRM1 1376/4885KMT2A 2494/4885
US-20220220147-A1 CD73 INHIBITORS ENTPD5, NT5E, ENTPD1 CHRM2 1316/4885CHRM1 1376/4885KMT2A 2494/4885
US-20220259253-A1 CD73 INHIBITORS ENTPD5, NT5E, ENTPD1 CHRM2 1316/4885CHRM1 1376/4885KMT2A 2494/4885
US-12018043-B2 CD73 inhibitors ENTPD5, NT5E, ENTPD1 CHRM2 1316/4885CHRM1 1376/4885KMT2A 2494/4885
US-11660311-B2 Cyclic dinucleotides as anticancer agents DPYD, CD38, DUT CHRM2 4802/4885CHRM1 4841/4885KMT2A 2358/4885
US-11858956-B2 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections MTAP, GALE, TPMT CHRM2 1101/4885CHRM1 697/4885KMT2A 536/4885
US-20220117995-A1 CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS DPYD, CD38, DUT CHRM2 4802/4885CHRM1 4841/4885KMT2A 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.